Roche Diagnostics part of development collaboration
19 November 2008 00:00 in Medical Company Product News
Roche Diagnostics has announced it is part of a collaboration with Merck Serono and Abbott in the development of the Biotechnology Cluster Rhine-Neckar (BioRN).
The cluster was recently given a federal grant worth 40 million euros (33.7 million pounds) by the German ministry for education and research and will be the host of this year's BIO-Europe event.
Roche and Merck Serono, along with other research institutions and biotechnology companies in the Rhine-Neckar region, already participate in projects towards the development of drugs and diagnostics.
Dr Jurgen Schwiezer, chief executive officer of the Roche Diagnostics division, said: "The success of the BioRN cluster, which brings together some 100 partners in business and research, rests partly on the excellent pioneering research being done here in the Rhine-Neckar region and on the presence of several major corporations."
Executive vice-president of research and development at Merck Serono added the network is set to mean a competitive advantage and a resulting benefit for patients.
The focus of the BioRN cluster is the development of innovative drugs, diagnostics and platform technologies in the field of cell-based and molecular medicine.
Based in Basel, Switzerland, Roche employs approximately 80,000 people, with sales in the pharmaceutical division reaching 36.8 billion Swiss francs in 2007.
Other news stories from 19/11/2008
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency